utd_medknow
Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1111
Small font sizeDefault font sizeIncrease font size
Navigate here
  Search
 
  
Resource links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (329 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Tables

 Article Access Statistics
    Viewed473    
    Printed16    
    Emailed0    
    PDF Downloaded19    
    Comments [Add]    

Recommend this journal

 

  Table of Contents  
LETTER TO THE EDITOR
Year : 2021  |  Volume : 58  |  Issue : 3  |  Page : 461-462
 

Lipid profile during chemotherapy in children with acute lymphoblastic leukemia


Division of Pediatric Hematology Oncology, Department of Pediatrics, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

Date of Submission03-Apr-2020
Date of Decision03-Apr-2020
Date of Acceptance12-Aug-2020
Date of Web Publication21-Jun-2021

Correspondence Address:
Vineeta Gupta
Division of Pediatric Hematology Oncology, Department of Pediatrics, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijc.IJC_280_20

Rights and Permissions



How to cite this article:
Madan D, Aggarwal P, Jain A, Gupta V. Lipid profile during chemotherapy in children with acute lymphoblastic leukemia. Indian J Cancer 2021;58:461-2

How to cite this URL:
Madan D, Aggarwal P, Jain A, Gupta V. Lipid profile during chemotherapy in children with acute lymphoblastic leukemia. Indian J Cancer [serial online] 2021 [cited 2021 Oct 27];58:461-2. Available from: https://www.indianjcancer.com/text.asp?2021/58/3/461/318896




Deranged lipid profile has been reported in children with acute lymphoblastic leukemia (ALL) during and following treatment.[1] The condition is under-diagnosed in India. This study was conducted to evaluate alterations in lipid levels and levels of amylase and lipase in 82 newly diagnosed patients with ALL in the age group one to 15 years admitted in university teaching hospital from September 2017 to August 2019. Estimation of serum amylase, lipase (U/L) and lipid profile (mg/dl) including very low density lipoprotein (VLDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and serum cholesterol was done at 0 month (at diagnosis), 1 month (end of induction phase), and 6 months (start of maintenance phase). Patients were divided into 3 age groups: 1–4, 5–9, and ≥10 years. Lipid levels were correlated with age, gender, risk stratification, cell lineage, and nutritional status. Weight-for-age was used in patients <5 years and body mass index was used for patients ≥5 years. Treatment was as per the children oncology group (COG) protocol. Fifty age- and gender-matched children were controls. Written informed consent was taken from parents/guardians. The study protocol was approved by the institutional ethics committee.

The baseline characteristics of the patients are presented in [Table 1]. All the mean values are accompanied with standard deviation. VLDL and triglycerides levels were high (51.17 ± 22.46 versus 34.02 ± 14.18, P = 0.002; 213.42 ± 91.09 versus 144.70 ± 66.41, P = 0.005) and HDL was low (25.97 ± 18.68 versus 42.81 ± 15.38, P = 0.008) at diagnosis compared to levels at 6 months in 1-4 years. In 5-9 years also, VLDL (45.04 ± 19.43 versus 31.95 ± 13.10, P = 0.012) and triglycerides (231.42 ± 91.09 versus 144.70 ± 66.41, P = 0.005) were high and HDL levels were low (34.61 ± 35.85 versus 48.01 ± 28.57, P = 0.004). No change was observed in LDL and cholesterol levels. In ≥10 years, only HDL levels were low (32.74 ±36.48 versus 46.81 ± 27.04, P = 0.002) at diagnosis. There was no significant change in VLDL, LDL, triglycerides, and cholesterol levels. Serum lipid levels of patients at diagnosis and controls were also compared in all three age groups. VLDL levels were high in patients 1-4 years of age (51.17 ± 22.46 versus 38.90 ± 13.90, P = 0.06). In 5–9 years of age, both VLDL and triglycerides were significantly increased (45.04 ± 19.43 versus 33.41 ± 27.79, P = 0.007 and 222.06 ± 95.73 versus 136.66 ± 51.46, P = 0.006 respectively). In ≥10 years, VLDL, LDL, HDL, triglycerides, and cholesterol levels were comparable to controls. No risk factors were identified for the deranged lipid profile. Serum amylase and lipase levels increased significantly at one month in patients <10 years only which normalized at 6 months. No patient had hypertriglyceridemia, pancreatitis, or thromboembolism.
Table 1: Baseline characteristics of the study population

Click here to view


Dyslipidemia is part of metabolic syndrome (MS) along with obesity, insulin resistance, and hypertension in survivors of ALL.[2] Older children and those treated with higher-risk therapy are at risk for severe hypertriglyceridemia (serum triglycerides ≥1000 mg/dL). Corticosteroids increase triglyceride synthesis and also increase the activity of lipoprotein lipase, whereas asparaginases can inhibit the activity of lipoprotein lipase. When steroids and asparaginase are given together, triglyceride-rich lipoproteins may be formed rapidly which are cleared inadequately resulting in hypertriglyceridemia.[3] This may be associated with pancreatitis and thromboembolism. In our patients, VLDL and triglycerides were raised and HDL levels were low at diagnosis all of which normalized at 6 months. VLDL and triglyceride levels at diagnosis were significantly higher than controls. The results are in agreement with other studies where lipid derangement was observed at the time of diagnosis which normalized during remission.[4],[5] It was suggested that lipid abnormalities observed at diagnosis may reflect altered nutritional states or altered lipid metabolism.[3] In contrast, one of the studies reported rising triglyceride and cholesterol levels during therapy and the reason was attributed to asparaginase treatment.[6] We could not identify any risk factor for deranged lipid profile which is also similar to the findings of another study.[5] It has been suggested that triglycerides are affected more by pegylated asparaginase than by native asparaginase especially when given together with dexamethasone.[7] We did not use pegylated asparaginase due to financial constraints and prednisolone was used during induction instead of dexamethasone. This may explain the low incidence of hypertriglyceridemia and pancreatitis in our study.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Morel S, Leahy J, Fournier M, Lamarche B, Garofalo C, Grimard G, et al. Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors. J Lipid Res 2017;58:982-92.  Back to cited text no. 1
    
2.
Mohapatra S, Bansal D, Bhalla AK, Verma Attri S, Sachdeva N, Trehan A, et al. Is there an increased risk of metabolic syndrome among childhood acute lymphoblastic leukemia survivors? A developing country experience. Pediatr Hematol Oncol 2016;33:136-49.  Back to cited text no. 2
    
3.
Bhojwani D, Darbandi R, Pei D, Ramsey LB, Chemaitilly W, Sandlund JT, et al. Severe hypertriglyceridemia during therapy for childhood acute lymphoblastic leukemia. Eur J Cancer 2014;50:2685-94.  Back to cited text no. 3
    
4.
Moschovi M, Trimis G, Apostolakou F, Papassotiriou I, Tzortzatou-Stathopoulou F. Serum lipid alterations in acute lymphoblastic leukemia of childhood. J Pediatr Hematol Oncol 2004;26:289-93.  Back to cited text no. 4
    
5.
Zalewska-Szewczyk B, Matusiak I, Wyka K, Trelinska J, Stolarska M, Mlynarski W. Changes in the lipid profile in children with acute lymphoblastic leukemia-the influence of the disease and its treatment. Med Wieku Rozwoj 2008;12:1035-40.  Back to cited text no. 5
    
6.
Cohen H, Bielorai B, Harats D, Taren A, Pinhas-Hamiel O. Conservative treatment of L-asparaginase associated lipid abnormalities in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010;54:703-6.  Back to cited text no. 6
    
7.
Finch ER, Smith CA, Yang W, Liu Y, Karnegay NM, Panetta JC. Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2020;67:e28040  Back to cited text no. 7
    



 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article
 

    

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow